Abstrato

IDegAsp provides simple intensification without the addition of another insulin injection and simple delivery system

Shizuka Kaneko*, Youhei Ueda, Yumiko Tahara

Insulin degludec (IDeg) is an ultra-long duration novel basal insulin analogue, with flat and stable glucose-lowering effect. Translating into lower rates of hypoglycemia, especially nocturnal episodes, compared to conventional basal insulin in patients with T2DM, and have the potential for flexible dosing times to accommodate varying lifestyles. A co-formulation of IDeg and the rapid-acting analogue insulin aspart (IAsp) results in the soluble co-formulation insulin degludec/insulin aspart (IDegAsp). This provides both mealtime coverage and full 24-h basal coverage in a single injection. We confirmed the effectiveness of the intensification of therapy by substitution of basal insulin or conventional premix insulin with newly premix insulin IDegAsp in uncontrolled patients by continuous glucose monitoring (CGM). Novel soluble co-formulation insulin degludec/insulin aspart, IDegAsp, provides a simple helpful intensification for poorly controlled T2DM patients on basal insulin and every T2DM patient administrated conventional premix. Using IDegAsp is a patient-friendly intensified insulin therapy from the point of view that it is simple delivery system without need for reconstitution before injection and with no need for additional insulin injections.